The Manning Lab is a multi-disciplinary research program group studying the development, validation, and translation of non-invasive molecular imaging metrics to assess disease progression and response to therapy. Projects within our program emphasize molecular imaging of cancer, and notably imaging-based assessment of response to anti-cancer pharmaceuticals in colorectal and breast cancer. We are actively engaged in advancing novel methods to image molecular events in both humans and animal models that include receptor expression, proliferation, angiogenesis, and apoptosis. Among these methods include validation of imaging probes for novel applications, as well as high-throughput small-molecule discovery to develop novel imaging compounds.
Dr. Tian’s research focuses on optical imaging models and reconstruction algorithms for in vivo optical tomographic imaging, including bioluminescence tomography, fluorescence molecular tomography, and Cerenkov luminescence tomography. He has developed various types of molecular imaging instrumentations, such as optical-CT-MRI-PET hybrid multimodality imaging system, optical projection tomography system, endoscopic Cerenkov luminescence imaging system, photoacoustic and fluorescence hybrid imaging system, etc. He has developed new artificial intelligence strategies for medical image quantitative analysis in Radiomics studies. Currently, he is translating novel intraoperative near-infrared fluorescence imaging technologies, including new optical molecular imaging systems and molecular probes, for navigating liver cancer, lung cancer, and breast cancer surgeries in multi-center clinical trials in China